US Patent 12121527 Anthracycline-based antibody drug conjugates having high in vivo tolerability

Is a

Patent

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

121215270

Patent Inventor Names

Remy Gebleux0

Ulf Grawunder0

Roger Beerli0

Date of Patent

October 22, 2024

Patent Application Number

169258020

Date Filed

July 10, 2020

Patent Citations

‌

US Patent 9163258 Method for the treatment of obesity

‌

US Patent 7462608 Non nucleoside reverse transcriptase inhibitors

‌

US Patent 8212009 Methods and compounds for lymphoma cell detection and isolation

‌

US Patent 8703801 Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications

‌

US Patent 9150647 Biological inhibitors of ROR1 capable of inducing cell death

‌

US Patent 9228023 Anti-ROR1 antibodies and methods of use for treatment of cancer

‌

US Patent 9242014 Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof

‌

US Patent 9266952 Antibodies against ROR1 and uses thereof

...

Patent Primary Examiner

CPC Code

...

Patent abstract

The present invention relates to antibody drug conjugates (ADCs) presenting improved properties of in vivo tolerability.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 12121527 Anthracycline-based antibody drug conjugates having high in vivo tolerability

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 12121527 Anthracycline-based antibody drug conjugates having high in vivo tolerability